Atypical antipsychotics: Matching receptor profile to individual patient's clinical profile

CNS Spectrums

Volumn 9, Issue 10 SUPPL. 11, 2004, Pages 6-14

  Shayegan, Darius K ^a   Stahl, Stephen M ^b  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; MONOAMINE; MUSCARINIC M1 RECEPTOR ANTAGONIST; NEUROTRANSMITTER RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; ZIPRASIDONE;

BINDING AFFINITY; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG BINDING; DRUG MECHANISM; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING;

EID: 8144220306     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025086     Document Type: Conference Paper

References (47)

1. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25:390-392.
2. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist -3(3 hydroxyphenyl)-N-n-propylpiperdine (preclamol) in schizophrenia. Biol Psychiatry. 1998;43:2-11.
3. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord. 2002;1:141-147.
4. Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry. 2003;64(suppl 8):15-21.
5. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord. 2001;67:213-219.
6. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
7. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
8. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:430-441.
9. de Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs. 2001;2:123-132.
10. Miyamoto S, Duncan GE, Goff DC, Lieberman JA. Therapeutics of schizophrenia. In: Davis K, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. (American College of Neuropsychopharmacology) Philadelphia, PA: Lippincott Williams & Wilkins; 2002;790-807.
11. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(Suppl 19):6-12.
12. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873-883.
13. Stahl SM. Hit-and-run actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J Clin Psychiatry. 2001;62:670-671.
14. Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs. 2004;18:597-616.
15. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24;192-208.
16. Bench CJ, Lammertsma AA, Dolan RJ, et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology (Berl). 1993;112:308-314.
17. Bench CJ, Lammertsma AA, Grasby PM, et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by position emission tomography. Psychopharmacology (Berl). 1996;124:141-147.
18. Fischman AJ, Bonab AA, Babich JW, et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic, ziprasidone. J Pharmacol Exp Ther. 1996;279:939-947.
19. Mamo D, Kapur S. A PET study of dapamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825.
20. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-69.
21. Faraone SV, Glatt SJ, Su J, Tsuang MT Three potential susceptibility loci shown by a genome-wide scan for regions influencing the age at onset of mania. Am J Psychiatry. 2004;161:625-630.
22. Blumberg HP, Kauffman J, Martin A, Charney DS, Krystal JH, Peterson BS. Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann NY Acad Sci. 2004;1021:376-383.
23. Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 1997;27(1):79-82.
24. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998;95(2):735-40.
25. Goldman-Rakic PS. The "psychic" neuron of the cerebral cortex. Ann N Y Acad Sci. 1999;868:13-26.
26. Weinberger DR. Dopamine, the prefrontal cortex, and a genetic mechanism of schizophrenia. In: Kapur S, Lecrubier Y, eds. Dopamine in the Pathophysiology and Treatment of Schizophrenia: New Findings. London, England: Martin Dunitz; 2003:129-154.
27. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry advance online publication. 2004;20:1-29.
28. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci. 2002;22(7):2843-2854.
29. Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience. 2002;111(1):163-176.
30. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. Br J Pharmacol. 1997;120:865-875.
31. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001a;922:9-20.
32. Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002;27:430-441.
33. Pozzi L, Acconcia S, Ceglia I, Invernizzi RW, Samanin R. Stimulation of 5-hydroxytryptamine (5-HT[2C]) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem. 2002;82:93-100.
34. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
35. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003;64:110-111.
36. Bremner JD, Vythilingam M, Ng CK, et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA. 2003;289:3125-3134.
37. Mazei MS, Pluto CP, Kirkbride B, Pehek EA. Effects of catecholamine uptake blockers in the caudate-putame and subregions of the medial prefrontal cortex of the rat. Brain Res. 2002;936:58-67.
38. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295:853-861.
39. Sumiyoshi T, Jayathilake K, Meltzer HY. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr Res. 2003;59:7-16.
40. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531.
41. Tauscher J, Kapur S, Verhoeff NP, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002;59:514-520.
42. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 1993;16:387-400.
43. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
44. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 1990;157:799-811.
45. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325-339.
46. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.
47. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York, NY: Cambridge University Press; 1996.